BioLife Solutions Inc (BLFS)vsJohnson & Johnson (JNJ)
BLFS
BioLife Solutions Inc
$38.61
0.00%
HEALTHCARE · Cap: $1.89B
JNJ
Johnson & Johnson
$254.01
-0.69%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 93008% more annual revenue ($99.33B vs $106.69M). BLFS leads profitability with a 54.3% profit margin vs 16.2%. JNJ appears more attractively valued with a PEG of 2.82. JNJ earns a higher WallStSmart Score of 57/100 (C).
BLFS
Hold46
out of 100
Grade: D+
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.6%
Fair Value
$21.68
Current Price
$38.61
$16.93 premium
Margin of Safety
-76.5%
Fair Value
$143.78
Current Price
$254.01
$110.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Strong operational efficiency at 25.1%
Generating 3.4B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 54.3% and operating margin at 6.0%. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : BLFS
The primary concerns for BLFS are P/E Ratio, Market Cap, PEG Ratio.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
BLFS profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.82 — expect wider price swings.
BLFS is growing revenue faster at 21.5% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 46/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?